Cyril Amarchand Mangaldas advised Laurus Labs on investment in Immunoadoptive Cell Therapy
Cyril Amarchand Mangaldas advised Laurus Labs on investment in Immunoadoptive Cell Therapy Cyril Amarchand Mangaldas acted as legal counsel to Laurus Labs Limited (Laurus) on investment of INR 46 crores (appox.) by way of primary investment pursuant to which Laurus subscribed to 26.62% of the share capital of Immunoadoptive Cell Therapy Private Limited (ImmunoACT) on a fully diluted...
ToRead the Full Story, Subscribe to
Access the exclusive LEGAL ERAStories,Editorial and Expert Opinion
Cyril Amarchand Mangaldas advised Laurus Labs on investment in Immunoadoptive Cell Therapy
Cyril Amarchand Mangaldas acted as legal counsel to Laurus Labs Limited (Laurus) on investment of INR 46 crores (appox.) by way of primary investment pursuant to which Laurus subscribed to 26.62% of the share capital of Immunoadoptive Cell Therapy Private Limited (ImmunoACT) on a fully diluted basis. ImmunoACT is engaged in the business of researching, developing, conducting trials, reorganizing, promoting, acquiring, accomplishing engineered cells for diagnosis and/or treatments for various disorders including cancer, auto immune disease, etc.
The General Corporate Practice of Cyril Amarchand Mangaldas advised on the Transaction. The Transaction team was led by Nagavalli G, Partner; with support from Ayushi Mishra, Senior Associate; Mahima Goel, Associate; and Jayant Belgaumkar, Associate.
The Diligence team comprised of Ayushi Mishra, Senior Associate; Mahima Goel, Associate and Jayant Belgaumkar, Associate.
Ashwin Sapra, Partner; Biplab Lenin, Principal Associate and Kartik Jain, Associate advised on pharmaceutical, healthcare regulatory and intellectual property aspects of the transaction.
The Transaction also involved certain other investors who invested INR 9.75 crores by way of primary and secondary investment pursuant to which the other investors shall collectively hold 5.64% of the share capital of ImmunoACT on a fully diluted basis.
